Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases

Published

2 July 2026

Estimated value

€252,000,000

Procedure

neg-w-call

Lots

2

Notice number

00456593-2026

Reference

43602e74-f078-4752-9f28-d52e0225ceb2

Official source

Official source

CPV codes

• 73000000Servicios de investigación y desarrollo y servicios de consultoría conexos

Description

This call for tenders aims at speeding up the development of promising Next Generation Therapeutics for Infectious Diseases by adopting a competitive development in phases, under Pre-Commercial Procurement (PCP). The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, ARDS or sepsis resulting from infections, including pathogen-targeted therapeutics (but not small molecules or monoclonal antibodies) and host-targeted therapeutics, among which but not only direct-acting antivirals, indirect-acting antivirals and novel immune modulators. It may also cover innovative combinations therapies and products designed to be administered through alternative routes to IV. Broad spectrum therapeutics, pathogen-agnostic therapeutics and therapeutics that could reduce or counteract the emergence of viral resistance are of particular interest.

Frequently asked questions

What is the estimated value of this tender?

The estimated value published by the buyer is €252,000,000.

Who is the buyer of this tender?

The contracting authority is Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency (European Union).